Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SHE:301126)
China · Delayed Price · Currency is CNY 12.88
+0.02 (0.16%)
At close: Feb 27, 2026
SHE:301126 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 5,367 | 5,220 | 3,894 | 3,279 | 2,586 | 2,335 |
Other Revenue | 13.33 | 13.33 | 9.37 | 13.5 | 6.12 | 5.15 |
| 5,380 | 5,233 | 3,904 | 3,292 | 2,592 | 2,340 | |
Revenue Growth (YoY) | 5.30% | 34.07% | 18.56% | 27.01% | 10.79% | -4.75% |
Cost of Revenue | 4,405 | 4,197 | 3,335 | 2,901 | 2,292 | 2,073 |
Gross Profit | 975.7 | 1,036 | 568.05 | 391.68 | 300.35 | 266.32 |
Selling, General & Admin | 789.23 | 821.41 | 421.39 | 254.61 | 148.43 | 132.68 |
Research & Development | 14.25 | 16.26 | 7.17 | 0.52 | - | - |
Other Operating Expenses | -10.16 | -6.21 | 1.97 | 11.58 | 10.13 | 8.91 |
Operating Expenses | 803.51 | 839.34 | 445.44 | 283.46 | 172.06 | 145.76 |
Operating Income | 172.19 | 196.75 | 122.61 | 108.23 | 128.3 | 120.56 |
Interest Expense | -112.61 | -107.82 | -69.51 | -40.75 | -34.89 | -31.55 |
Interest & Investment Income | 2.83 | 3.54 | 5.3 | 7.74 | 1.05 | 0.81 |
Other Non Operating Income (Expenses) | -5.68 | -6.36 | -9.25 | -4.74 | -2.68 | -2.19 |
EBT Excluding Unusual Items | 56.73 | 86.11 | 49.15 | 70.48 | 91.79 | 87.63 |
Impairment of Goodwill | -12.61 | -12.61 | - | - | - | - |
Gain (Loss) on Sale of Investments | -0.38 | -0.38 | -0.15 | - | - | - |
Gain (Loss) on Sale of Assets | 2.49 | 1.38 | 1.11 | 0.32 | - | -0 |
Asset Writedown | -0.71 | -0.06 | -0.48 | -0.01 | - | - |
Other Unusual Items | -0.77 | 1.55 | -1.07 | 5.39 | 4.22 | 2.5 |
Pretax Income | 44.74 | 76 | 48.55 | 76.17 | 96.01 | 90.13 |
Income Tax Expense | 16.79 | 24.66 | 10.54 | 20.85 | 27.75 | 25.27 |
Earnings From Continuing Operations | 27.96 | 51.33 | 38.01 | 55.32 | 68.26 | 64.85 |
Minority Interest in Earnings | -32.74 | -24.76 | -3.71 | -4.25 | - | - |
Net Income | -4.78 | 26.57 | 34.3 | 51.08 | 68.26 | 64.85 |
Net Income to Common | -4.78 | 26.57 | 34.3 | 51.08 | 68.26 | 64.85 |
Net Income Growth | - | -22.52% | -32.85% | -25.17% | 5.25% | -26.01% |
Shares Outstanding (Basic) | 205 | 204 | 202 | 204 | 155 | 154 |
Shares Outstanding (Diluted) | 205 | 204 | 202 | 204 | 155 | 154 |
Shares Change (YoY) | 0.33% | 1.32% | -1.25% | 31.70% | 0.47% | 0.41% |
EPS (Basic) | -0.02 | 0.13 | 0.17 | 0.25 | 0.44 | 0.42 |
EPS (Diluted) | -0.02 | 0.13 | 0.17 | 0.25 | 0.44 | 0.42 |
EPS Growth | - | -23.53% | -32.00% | -43.18% | 4.76% | -26.32% |
Free Cash Flow | 1.72 | -163.1 | -199.57 | -702.69 | -195.1 | -197.41 |
Free Cash Flow Per Share | 0.01 | -0.80 | -0.99 | -3.44 | -1.26 | -1.28 |
Dividend Per Share | 0.104 | 0.082 | 0.040 | 0.029 | 0.034 | - |
Dividend Growth | 159.50% | 104.50% | 37.93% | -14.71% | - | - |
Gross Margin | 18.14% | 19.80% | 14.55% | 11.90% | 11.59% | 11.38% |
Operating Margin | 3.20% | 3.76% | 3.14% | 3.29% | 4.95% | 5.15% |
Profit Margin | -0.09% | 0.51% | 0.88% | 1.55% | 2.63% | 2.77% |
Free Cash Flow Margin | 0.03% | -3.12% | -5.11% | -21.34% | -7.53% | -8.44% |
EBITDA | 365.04 | 342.7 | 206.05 | 130.85 | 142.38 | 133.15 |
EBITDA Margin | 6.78% | 6.55% | 5.28% | 3.98% | 5.49% | 5.69% |
D&A For EBITDA | 192.85 | 145.96 | 83.44 | 22.63 | 14.08 | 12.59 |
EBIT | 172.19 | 196.75 | 122.61 | 108.23 | 128.3 | 120.56 |
EBIT Margin | 3.20% | 3.76% | 3.14% | 3.29% | 4.95% | 5.15% |
Effective Tax Rate | 37.52% | 32.46% | 21.72% | 27.37% | 28.90% | 28.04% |
Revenue as Reported | 5,380 | 5,233 | 3,904 | 3,292 | 2,592 | 2,340 |
Advertising Expenses | - | 77.9 | 34.34 | 8.87 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.